(Sharecast News) - Eli Lilly significantly raised its full-year revenue forecast by $3bn on Thursday, after reporting a strong second quarter driven by the robust performance of its blockbuster weight loss and diabetes drugs Zepbound and Mounjaro.

The Indianapolis-based pharmaceutical giant reported a 36% increase in revenue for the quarter,...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE